Daiichi Sankyo
Global pharmaceutical company engaged in discovery, development, manufacturing and commercialization of medicines with a major focus on oncology. Core technical priorities include antibody-drug conjugates, nucleic acid and viral-based therapeutics, translational research with biomarker-driven patient selection, and digital transformation of R&D and laboratory operations. The company maintains global manufacturing and supply capabilities and operates structured governance, audit, risk-management, quality and regulatory systems.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Therapy for drug-resistant cancer by administration of anti-HER2 antibody/drug conjugate
US-12698342-B2
View DetailsImmune inducer containing polynucleotide-peptide conjugate and pharmaceutical composition containing same
US-12685780-B2
View Details
Therapy for drug-resistant cancer by administration of anti-HER2 antibody/drug conjugate
US-12698342-B2
View DetailsImmune inducer containing polynucleotide-peptide conjugate and pharmaceutical composition containing same
US-12685780-B2
View DetailsProducts
Enhertu (trastuzumab deruxtecan)
Antibody-drug conjugate approved for multiple HER2-expressing cancers with ongoing global clinical programs.
Datroway (TROP2-directed ADC)
TROP2-targeted antibody-drug conjugate in clinical development for triple-negative and other TROP2-expressing tumors.
Vanflyta (FLT3 inhibitor)
Orally administered FLT3-targeted kinase inhibitor developed for FLT3-ITD positive acute myeloid leukemia.
mRNA COVID-19 vaccine candidate (DS-5670)
mRNA-based vaccine candidate advanced into clinical development with regulatory filings in Japan.
DELYTACT (oncolytic virus therapy)
Oncolytic viral therapy approved in Japan for treatment of certain malignant gliomas.
EZH1/2 inhibitor (EZHARMIA)
Dual EZH1/EZH2 epigenetic inhibitor developed for peripheral T-cell lymphoma and related hematologic malignancies.
Enhertu (trastuzumab deruxtecan)
Antibody-drug conjugate approved for multiple HER2-expressing cancers with ongoing global clinical programs.
Datroway (TROP2-directed ADC)
TROP2-targeted antibody-drug conjugate in clinical development for triple-negative and other TROP2-expressing tumors.
Vanflyta (FLT3 inhibitor)
Orally administered FLT3-targeted kinase inhibitor developed for FLT3-ITD positive acute myeloid leukemia.
mRNA COVID-19 vaccine candidate (DS-5670)
mRNA-based vaccine candidate advanced into clinical development with regulatory filings in Japan.
DELYTACT (oncolytic virus therapy)
Oncolytic viral therapy approved in Japan for treatment of certain malignant gliomas.
EZH1/2 inhibitor (EZHARMIA)
Dual EZH1/EZH2 epigenetic inhibitor developed for peripheral T-cell lymphoma and related hematologic malignancies.
Services
Manufacturing and contract production services for vaccines and biological products, including production capacity used under outsourcing agreements.
Manufacturing and contract production services for vaccines and biological products, including production capacity used under outsourcing agreements.
Expertise Areas
- Oncology drug discovery and development
- Antibody-drug conjugate platforms
- Clinical trial design and global operations
- Translational research and biomarker development
Key Technologies
- Antibody–drug conjugate linker–payload chemistries
- mRNA and nucleic-acid delivery platforms
- Oncolytic and viral vector platforms
- Small-molecule targeted drug discovery
News & Updates
Selection for the national DX Stocks recognition reflecting progress in digital transformation initiatives.
Recognition for the company's ADC platform technology at an industry ADC awards event.
Regulatory expedited designation granted in Japan for an EZH1/2 dual inhibitor program.
Award recognizing contributions to medical research and development.
Announced multi-billion yen manufacturing investment to expand specialized ADC production capabilities.
Selection for the national DX Stocks recognition reflecting progress in digital transformation initiatives.
Recognition for the company's ADC platform technology at an industry ADC awards event.
Regulatory expedited designation granted in Japan for an EZH1/2 dual inhibitor program.
Award recognizing contributions to medical research and development.
Announced multi-billion yen manufacturing investment to expand specialized ADC production capabilities.